Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427263 | 0.95 | HRH3 (0.71) | HRH3NPC1TP53MAPTTSHR | |
| Trifluoroacetic Acid SCHEMBL2423022 | 0.91 | HRH3 (0.64) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2422813 | 0.89 | HRH3 (0.62) | HRH3MAPTRAB9ASMN1; SMN2KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2426736 | 0.89 | HRH3 (0.62) | HRH3NPC1MAPTRAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL2421907 | 0.88 | HRH3 (0.59) | HRH3TP53MAPTSMN1; SMN2KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2419130 | 0.88 | HRH3 (0.71) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2420644 | 0.88 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2418500 | 0.87 | HRH3 (0.68) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2424041 | 0.86 | HRH3 (0.72) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2419561 | 0.86 | HRH3 (0.88) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618159-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | HRH3 1/4885NPC1 1047/4885TP53 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.